TMS for Nicotine Addiction
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to help people addicted to nicotine using transcranial magnetic stimulation (TMS). Researchers aim to identify the optimal brain target for TMS to reduce cravings and improve decision-making in smokers. The study includes active TMS sessions (10-Hz TMS to the DLPFC) and a sham session for comparison. Individuals addicted to nicotine, in stable health, and without addiction treatment in the past 30 days may qualify for this trial. As an unphased trial, it offers a unique opportunity to contribute to groundbreaking research that could lead to new treatments for nicotine addiction.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it excludes those on uninterruptable central nervous system medication. It's best to discuss your specific medications with the trial team.
What prior data suggests that these targeting techniques are safe for nicotine addiction?
Research has shown that using a 10-Hz magnetic pulse on the front part of the brain is generally safe for people trying to quit smoking. Studies have found that headaches are the most common side effect, but they are usually mild. Importantly, no seizures were reported in these studies, indicating good safety. Overall, participants in similar studies have tolerated the treatment well.12345
Why are researchers excited about this trial?
Researchers are excited about using 10-Hz Transcranial Magnetic Stimulation (TMS) for nicotine addiction because it offers a novel approach compared to existing treatments like nicotine replacement therapies and medications such as varenicline. Unlike these methods, TMS targets the brain's dorsolateral prefrontal cortex directly, potentially altering brain circuits associated with addiction. This non-invasive technique could reduce cravings and dependence without the side effects commonly associated with current pharmacological options. By offering a new mechanism of action, TMS holds promise as an innovative treatment pathway for those struggling with nicotine addiction.
What evidence suggests that this TMS protocol is effective for nicotine addiction?
Research shows that a treatment called 10-Hz repetitive transcranial magnetic stimulation (rTMS) can help reduce cravings and addiction to nicotine. This trial will compare the effects of active 10-Hz TMS to the DLPFC with Sham TMS. In one study, participants who received 10 sessions of rTMS experienced a significant decrease in withdrawal symptoms and cravings. Another study found that the 10-Hz frequency was more effective at reducing smoking and nicotine dependence than other frequencies. Additionally, rTMS has shown promise as an additional treatment to help people quit smoking by lowering their dependence on nicotine. While results can vary, these findings suggest that rTMS may be helpful for those who want to quit smoking.16789
Who Is on the Research Team?
Travis E Lalta, PhD
Principal Investigator
Rutgers University
Are You a Good Fit for This Trial?
This trial is for individuals aged 18-55 with nicotine addiction who are in good mental and physical health, can follow the study plan, and haven't had substance abuse treatment recently. Pregnant women or those with brain lesions, metal implants affecting MRI scans, or certain neurological conditions cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Session A
Participants undergo MRI scanning and receive structural, fMRI, DWI, and resting-state FC scans
Sessions B and C
Participants receive rTMS at different prefrontal targets and complete T-maze and PST tasks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- 10-Hz TMS to the DLPFC
- Sham TMS-DLPFC
10-Hz TMS to the DLPFC is already approved in United States, European Union, Canada for the following indications:
- Major Depressive Disorder (MDD)
- Obsessive-Compulsive Disorder (OCD)
- Post-Traumatic Stress Disorder (PTSD)
- Major Depressive Disorder (MDD)
- Major Depressive Disorder (MDD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor